Renishaw (LON:RSW) had its price objective upped by analysts at Deutsche Bank from GBX 3,630 ($48.61) to GBX 4,255 ($56.98) in a research note issued to investors on Monday. The brokerage presently has a “sell” rating on the stock. Deutsche Bank’s price objective suggests a potential downside of 17.94% from the stock’s current price.
A number of other equities research analysts also recently issued reports on RSW. Citigroup reissued a “neutral” rating and issued a GBX 470 ($6.29) price target on shares of Renishaw in a research note on Monday, October 30th. Peel Hunt boosted their price target on shares of Renishaw from GBX 3,200 ($42.86) to GBX 4,200 ($56.25) and gave the company a “hold” rating in a research note on Tuesday, August 8th. Barclays upped their target price on shares of Renishaw from GBX 2,620 ($35.09) to GBX 3,880 ($51.96) and gave the stock an “underweight” rating in a research note on Thursday, August 17th. Investec reaffirmed a “hold” rating on shares of Renishaw in a research note on Friday, August 25th. Finally, Numis Securities reaffirmed an “add” rating and set a GBX 5,200 ($69.64) target price on shares of Renishaw in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating and five have given a hold rating to the stock. Renishaw presently has an average rating of “Hold” and a consensus price target of GBX 3,432.57 ($45.97).
Shares of Renishaw (LON RSW) opened at GBX 5,185 ($69.44) on Monday. Renishaw has a 52 week low of GBX 2,355 ($31.54) and a 52 week high of GBX 5,635 ($75.47).
Renishaw plc is a metrology company. The Company operates through two segments: metrology and healthcare. The Company’s metrology products are used in the fields of industrial automation and motion systems. The healthcare products include engineering solutions for stereotactic neurosurgery, diagnosis of infectious diseases, analytical tools that identify and characterize the chemistry and structure of materials, supply of implants to hospitals and specialist design centers for craniomaxillofacial surgery, and products and services that allow dental laboratories to manufacture dental restorations.
Receive News & Ratings for Renishaw plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renishaw plc and related companies with MarketBeat.com's FREE daily email newsletter.